EUCTR2007-005881-11-NL进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of a sulfonylurea in patients with type 2 diabetes not adequately controlled with sulfonylurea - GETGOAL-S
Sanofi-Aventis Recherche&Développement0 个研究点目标入组 855 人开始时间: 2008年7月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 855
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients meeting all the following inclusion criteria will be screened:
- •- Patients with type 2 diabetes mellitus, as defined by WHO (Fasting plasma glucose =7 mmol/L (126 mg/dL) or 2 hours postprandial plasma glucose =11.1 mmol/L (200 mg/dL)), diagnosed for at least 1 year before screening visit, insufficiently controlled with a sulfonylurea alone or with sulfonylurea in association with metformin
- •- Written informed consent obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
- •Patients meeting all the following inclusion criteria will be screened:
- •- Patients with type 2 diabetes mellitus, as defined by WHO (Fasting plasma glucose =7 mmol/L (126 mg/dL) or 2 hours postprandial plasma glucose =11.1 mmol/L (200 mg/dL)), diagnosed for at least 1 year before screening visit, insufficiently controlled with a sulfonylurea alone or with sulfonylurea in association with metformin
- •- Written informed consent obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Related to study methodo:
- •- HbA1c <7.0% or HbA1c >10% at screening
- •- At the time of screening age < legal age of majority
- •- Women of childbearing potential with no effective contraceptive method (Women of childbearing potential (pre-menopausal, not surgically sterile women for at least 3 months prior to the time of screening) must have a confirmed negative serum ß-hCG pregnancy test at screening Visit. They must use an effective contraceptive method throughout the study, and agree to repeat serum ß-HCG pregnancy test at designated visits)
- •- Type 1 diabetes mellitus
- •- Sulfonylurea less than the max effective dose according to local labeling
- •- Sulfonylurea not at a stable dose for at least 3 months prior to screening
- •- In case of treatment with metformin in association with sulfonylurea, no stable treatment with metformin of at least 1.5 g/day (except at least 0.75 g/day in JP and at least 1.0 g/day in KR), for at least 3 months prior to screening visit
- •- Fasting Plasma Glucose at screening >250 mg/dL (>13.9 mmol/L)
- •- History of hypoglycemia unawareness
- •- Body Mass Index (BMI) =20 kg/m²
- •- Weight change of more than 5 kg during the 3 months preceding the screening visit
- •- History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease
- •- History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening
- •- Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to the time of screening
- •- Within the last 6 months prior to screening: History of myocardial infarction, stroke, or heart failure requiring hospitalization
- •- Known history of drug or alcohol abuse within 6 months prior to the time of screening
- •- Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the proto or interpretation of the study results difficult, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period
- •- Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic or diastolic blood pressure >180 mmHg or >95 mmHg, respectively
- •- Laboratory findings at the time of screening: AST, ALT or ALP: >2 times the upper limit of the normal laboratory range, Amylase and/or lipase: >3 times the upper limit of the normal laboratory range, Total bilirubin: >1.5 times the upper limit of the normal laboratory range (except in case of Gilbert’s syndrome), Hemoglobin <11 g/dL and/or neutrophils < 1500/mm3 and/or platelets <100 000/mm3, Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody
- •- Any clinically significant abnormality identified on physical examination, laboratory tests or vital signs at the time of screening that in the judgment of the investigator or any sub investigator would preclude safe completion of the study or constrains efficacy assessment
- •- Patients considered by the investigator or any sub investigator as inappropriate for this study for any reason (eg, impossibility to meet specific proto requirements, such as scheduled visits, being able to do self-injections, other study staff or relative thereof directly involved in the conduct of the proto...)
- •- Patients with condition/concomitant diseases making them non evaluable for the efficacy assessment
- •Related to study methodo:
- •- HbA1c <7.0% or HbA1c >10% at screening
- •- At the time of screening age < legal age of majority
- •- Women of childbearing potential with no effective contraceptive method (Women of childbearing potential (pre-menopausal, not surgically sterile women for at least 3 months prior to the time of screening) must have a confirmed negative serum ß-hCG pregnancy test at screening Visit. They must use an effective contraceptive method throughout the study, and agree to repeat serum ß-HCG pregnancy test at designated visits)
- •- Type 1 diabetes mellitus
- •- Sulfonylurea less than the max effective dose according to local labeling
- •- Sulfonylurea not at a stable dose for at least 3 months prior to screening
- •- In case of treatment with metformin in association with sulfonylurea, no stable treatment with metformin of at least 1.5 g/day (except at least 0.75 g/day in JP and at least 1.0 g/day in KR), for at least 3 months prior to screening visit
- •- Fasting Plasma Glucose at screening >250 mg/dL (>13.9 mmol/L)
- •- History of hypoglycemia unawareness
- •- Body Mass Index (BMI) =20 kg/m²
- •- Weight change of more than 5 kg during the 3 months preceding the screening visit
- •- History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease
- •- History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening
- •- Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to the time of screening
- •- Within the last 6 months prior to screening: History of myocardial infarction, stroke, or heart failure requiring hospitalization
- •- Known history of drug or alcohol abuse within 6 months prior to the time of screening
- •- Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the proto or interpretation of the study results difficult, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period
- •- Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic or diastolic blood pressure >180 mmHg or >95 mmHg, respectively
- •- Laboratory findings at the time of screening: AST, ALT or ALP: >2 times the upper limit of the normal laboratory range, Amylase and/or lipase: >3 times the upper limit of the normal laboratory range, Total bilirubin: >1.5 times the upper limit of the normal laboratory range (except in case of Gilbert’s syndrome), Hemoglobin <11 g/dL and/or neutrophils < 1500/mm3 and/or platelets <100 000/mm3, Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody
- •- Any clinically significant abnormality identified on physical examination, laboratory tests or vital signs at the time of screening that in the judgment of the investigator or any sub investigator would preclude safe completion of the study or constrains efficacy assessment
- •- Patients considered by the investigator or any sub investigator as inappropriate for this study for any reason (eg, impossibility to meet specific proto requirements, such as scheduled visits, being able to do self-injections, other study staff or relative thereof directly involved in the conduct of the proto...)
- •- Patients with condition/concomitant diseases making them non evaluable for the efficacy assessment
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety of lixisenatide versus placebo on top of basal insulin and/or oral antidiabetic treatment in older type 2 diabetic patientsEUCTR2012-003292-19-DESanofi-Aventis Recherche & Développement340
进行中（未招募）
不适用
Efficacy and safety of lixisenatide versus placebo on top of basal insulin and/or oral antidiabetic treatment in older type 2 diabetic patientsType 2 Diabetes mellitusMedDRA version: 17.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-003292-19-SESanofi-Aventis Recherche & Développement340
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 in patients with Type 2 diabetes insufficiently controlled with basal insulin. - GETGOALEUCTR2007-005886-36-FRSanofi -Aventis Recherche & Développement450
已完成
2 期
Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CTRI/2010/091/000285ovartis Healthcare Private Limited360
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 in patients with Type 2 diabetes insufficiently controlled with basal insulin. - GETGOALType II DiabetesMedDRA version: 10.1Level: LLTClassification code 10067585Term: <Manually entered code. Term in E.1.1>EUCTR2007-005886-36-GBSanofi -Aventis Recherche & Développement450